GlassScriptPhysician profile
James M Shettsline
NPI 1922158849
$9,121.32
in general payments reported to CMS, 2019-2025
38 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,106 · 2020: $1,096 · 2021: $1,969 · 2022: $1,704 · 2023: $716 · 2024: $1,104 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,941.39 | 2020-2024 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $685.54 | 2019-2024 | Airsupra, Farxiga |
| Allergan, INC. | $611.20 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.33 | 2019-2023 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $457.09 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $453.67 | 2020-2021 | |
| Pfizer INC. | $426.07 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $411.88 | 2019-2024 | Trintellix |
| Collegium Pharmaceutical, INC. | $302.74 | 2019-2024 | Xtampza, Belbuca |
| Janssen Pharmaceuticals, INC | $246.47 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $242.49 | 2024 | Orladeyo |
| Otsuka America Pharmaceutical, INC. | $237.30 | 2019-2022 | |
| Insmed, INC. | $231.89 | 2019 | |
| Novo Nordisk INC | $216.17 | 2020-2025 | Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $207.88 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Shettsline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.